Profile data is unavailable for this security.
About the company
EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS, formerly known as Eczacibasi Ilac Sanayi ve Ticaret A.S., (EIS) is a Turkey-based company active in the pharmaceutical industry through its subsidiaries, affiliates and joint ventures. Its product portfolio consists of drugs for human health, veterinary drugs and personal care products, such as body and facial creams, hair gels, deodorants and various other products. The Company is also engaged in real estate development and construction through its subsidiary, Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., formerly known as Eczacibasi Insaat ve Ticaret A.S. Its subsidiaries also include Eczacibasi Ilac Ticaret A.S. (EIT), EHP Eczacibasi Health Care Products Joint Stock Co. (EHP), and Eczacibasi Gayrimenkul Gelistirme ve Yatirim A.S., among others. EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a member of Eczacibasi Group of Companies.
- Revenue in TRY (TTM)8.89bn
- Net income in TRY2.44bn
- Incorporated1951
- Employees1.10k
- LocationEIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret ASBuyukdere Cad. Ali Kaya Sok. No:5 LeventISTANBUL 34394TurkeyTUR
- Phone+90 2 123508000
- Fax+90 2 123717399
- Websitehttps://www.eis.com.tr
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CF PharmTech Inc | 3.80bn | 174.81m | 81.33bn | 574.00 | 465.44 | 13.47 | 142.36 | 21.38 | 0.0761 | 0.0761 | 1.65 | 2.63 | -- | -- | -- | -- | -- | -- | -- | -- | 80.18 | -- | 4.60 | -- | 1.89 | -- | 0.076 | -- | 9.23 | -- | -33.53 | -- | -- | -- |
| Beijing Foyou Pharma Co Ltd | 21.58bn | 2.92bn | 81.41bn | 3.64k | 27.24 | 3.41 | -- | 3.77 | 0.9863 | 0.9863 | 7.28 | 7.87 | 0.733 | 3.27 | 9.59 | 938,316.50 | 9.99 | 12.53 | 12.82 | 17.64 | 65.17 | 68.01 | 13.62 | 13.02 | 2.52 | -- | 0.0077 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 5.37bn | 45.97m | 81.76bn | 1.06k | 1,777.28 | 7.82 | -- | 15.22 | 0.0179 | 0.0179 | 2.09 | 4.06 | 0.2441 | 2.40 | 4.06 | 802,822.70 | 0.2089 | 0.0036 | 0.2479 | 0.0042 | 85.48 | 91.31 | 0.8557 | 0.0181 | 1.79 | -0.6319 | 0.4834 | 0.00 | 25.63 | 30.51 | -228.97 | -- | 15.08 | -- |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 8.89bn | 2.44bn | 82.98bn | 1.10k | 34.07 | 1.45 | 25.38 | 9.33 | 3.55 | 3.55 | 12.98 | 83.78 | 0.1393 | 3.47 | 5.91 | 8,173,382.00 | 3.81 | 6.40 | 4.07 | 6.86 | 26.87 | 33.31 | 27.39 | 40.47 | 1.87 | -- | 0.0602 | 27.65 | -6.28 | 58.48 | -74.12 | 44.46 | 151.56 | 88.80 |
| Neuland Laboratories Ltd | 7.59bn | 862.66m | 83.42bn | 1.80k | 96.71 | -- | 65.95 | 11.00 | 139.62 | 139.62 | 1,227.57 | -- | -- | -- | -- | 8,755,392.00 | -- | 11.09 | -- | 14.93 | 49.33 | 49.56 | 11.37 | 14.20 | -- | 12.29 | -- | 6.80 | -5.24 | 14.13 | -13.32 | 45.82 | 33.44 | 43.10 |
| Aurinia Pharmaceuticals Inc | 11.60bn | 3.40bn | 83.74bn | 300.00 | 25.96 | 5.25 | 19.73 | 7.22 | 0.561 | 0.561 | 1.88 | 2.77 | 0.4937 | 0.7046 | 7.91 | -- | 14.46 | -18.84 | 16.88 | -20.97 | 88.93 | -- | 29.28 | -72.47 | 5.17 | -- | 0.1645 | -- | 33.97 | 274.78 | 107.37 | -- | 22.71 | -- |
| Sarepta Therapeutics Inc | 105.30bn | -11.84bn | 83.79bn | 1.37k | -- | 1.45 | -- | 0.7958 | -3.19 | -3.19 | 22.09 | 12.60 | 0.6806 | 0.6977 | 5.81 | 1,759,268.00 | -7.66 | -12.82 | -9.92 | -15.47 | 76.25 | 85.53 | -11.25 | -37.16 | 1.79 | -- | 0.4395 | -- | 52.97 | 37.94 | 143.89 | -- | 18.57 | -- |
| Fagron NV | 47.68bn | 4.45bn | 83.91bn | 3.99k | 18.63 | 3.20 | 12.88 | 1.76 | 1.18 | 1.18 | 12.64 | 6.86 | 0.849 | 3.54 | 10.06 | 233,481.60 | 7.96 | 7.68 | 9.87 | 9.64 | 45.75 | 43.75 | 9.37 | 9.96 | 1.06 | 6.00 | 0.4439 | 19.12 | 14.28 | 10.28 | 14.18 | 7.85 | 12.97 | 34.34 |
| Sihuan Pharmaceutical Holdings Group Ltd | 13.21bn | -507.95m | 85.23bn | 2.77k | -- | 3.10 | -- | 6.45 | -0.0098 | -0.0098 | 0.2566 | 0.5385 | 0.1894 | 1.49 | 3.86 | 887,928.40 | -3.05 | -3.60 | -5.01 | -5.05 | 66.29 | 73.13 | -16.08 | -19.74 | 1.61 | -1.36 | 0.1606 | -- | 2.18 | -7.96 | -301.10 | -- | -20.58 | 3.60 |
| Ocular Therapeutix Inc | 2.27bn | -11.60bn | 85.76bn | 325.00 | -- | 2.98 | -- | 37.84 | -1.44 | -1.44 | 0.2775 | 3.03 | 0.0821 | 1.99 | 1.65 | 159,849.20 | -42.01 | -38.63 | -45.31 | -43.31 | 87.35 | 90.18 | -511.90 | -229.54 | 15.32 | -- | 0.0983 | -- | -18.47 | 24.45 | -37.43 | -- | 70.20 | -- |
Data as of Feb 11 2026. Currency figures normalised to EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS's reporting currency: Turkish Lira TRY
1.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 5.08m | 0.74% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 1.86m | 0.27% |
| JPMorgan Investment Management, Inc.as of 08 Jan 2026 | 363.05k | 0.05% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 321.93k | 0.05% |
| BlackRock Investment Management (UK) Ltd.as of 30 Nov 2025 | 275.58k | 0.04% |
| Vanguard Asset Management Ltd.as of 31 Dec 2025 | 240.59k | 0.04% |
| Charles Schwab Investment Management, Inc.as of 08 Jan 2026 | 223.23k | 0.03% |
| Legal & General Investment Management Ltd.as of 31 Dec 2025 | 165.88k | 0.02% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 160.61k | 0.02% |
| BlackRock Advisors (UK) Ltd.as of 08 Jan 2026 | 136.17k | 0.02% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
